A Reappraisal of Women’s Health Initiative Estrogen-Alone Trial: Long-Term Outcomes in Women 50–59 Years of Age

Table 3

Number of women needed to treat (randomized to CEE) to prevent one woman from developing a myocardial infarction or global index event, women aged 50–59 years at trial entry, Women’s Health Initiative Estrogen-Alone Trial, and cumulative long-term outcomes.

Cumulative long-term (13-year median duration) outcomes
(intervention phase + postintervention phase)
Outcome	Number needed (95% CI) to treat	Effect
Myocardial infarction	76 (40.3–497.2)	1 less woman with a myocardial infarction
Global index^a	37 (19.6–312.6)	1 less woman with a global index event

A number needed to treat analysis for MI and global index for the intervention phase for women aged 50–59 years did not show a statistically significant difference in outcomes for the CEE versus placebo group.
^aA participant is counted as having a global index event if there is the diagnosis of one or more of the following occurring after randomization: coronary heart disease (nonfatal MI or coronary death), stroke, pulmonary embolism, invasive breast cancer, colorectal cancer, hip fracture, or death due to other causes.
CEE: conjugated equine estrogens; CI: confidence interval; MI: myocardial infarction; NS: not significant.
Derived (as per Methods Section) from data provided in [3].